Expats' dead bodies returned back to UAE from Delhi Airport; Indian govt's move shocks families in India

Mangalore, Jan 12: City police on Sunday arrested five people for their alleged involvement in a Rs 50 crore fraud by promising people higher monetary returns.

Police said that the arrested persons are Manjunath Nayak, a resident of Derebail; Denzil Mascarenhas, a Konchady resident; Ashok Naik, a Derebail resident; Vikas Nayak and Vishwanath Naik both residents of Bengaluru were arrested.

The arrested were employed in the ‘Speak and Group’ concern, started by Dhanush M K of Kundapur along with his friends. The firm had managed to collect huge sums of money from people, including NRIs by promising monthly four percent returns on their investment. The employees managed to entice people by showing them a few insurance schemes claiming higher returns.

Bengaluru, Feb 18: Passengers of the Ahmedabad bound GoAir flight had a providential escape when the engine of the aircraft while on the roll of take-off hit by a foreign object at the Kempe Gowda Bengaluru International Airport on Tuesday.

'The right engine of GoAir flight G8 802 from Ahmedabad to Bengaluru is suspected to have suffered from foreign object damage (FOD) while on take-off roll,' an official statement said.

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.